bioAffinity to Share Data on New Asthma and COPD Inflammation Test at CHEST 2026
bioAffinity Technologies will present positive research data at CHEST 2026 on a new test under development. The test is designed to measure lung inflammation associated with asthma and COPD and drug-related receptors. The company announced the upcoming presentation in a press release.
bioAffinity Technologies plans to present positive research data at CHEST 2026 for a new test that remains under development. The company says the test is designed to measure lung inflammation associated with asthma and COPD, as well as drug-related receptors. The upcoming presentation was announced in a press release. In the broader field of respiratory medicine, tools that assess inflammation are relevant to understanding asthma and COPD, but this announcement offers no further details about the test’s performance, availability, or clinical use.
If the test advances, people with asthma or COPD and their clinicians could gain another way to assess inflammation, potentially informing treatment discussions. Drug-related receptor measurement may also interest researchers studying therapies, though any impact depends on data quality and validation. For now, the announcement is a conference presentation, so patients and providers may see no immediate change. Access, cost, and clinical adoption would likely shape any broader societal effect.